Home » Stocks » SCPH

scPharmaceuticals Inc. (SCPH)

Stock Price: $7.07 USD 0.55 (8.44%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $7.20 +0.13 (1.84%) Jan 22, 6:51 PM
Market Cap 193.16M
Revenue (ttm) n/a
Net Income (ttm) -35.24M
Shares Out 27.32M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $7.07
Previous Close $6.52
Change ($) 0.55
Change (%) 8.44%
Day's Open 6.52
Day's Range 6.52 - 7.20
Day's Volume 206,558
52-Week Range 5.17 - 10.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch invest...

Zacks Investment Research - 1 month ago

scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in ...

Benzinga - 1 month ago

Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachus...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential ...

GlobeNewsWire - 2 months ago

Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential ...

Zacks Investment Research - 3 months ago

scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 7 months ago

scPharmaceuticals has created proprietary formulations of widely used, generically available IV drugs that can be more easily administered subcutaneously.

The Motley Fool - 8 months ago

The pharmaceutical company priced a secondary offering to raise capital.

GlobeNewsWire - 1 year ago

Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020

About SCPH

scPharmaceuticals, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibioti... [Read more...]

Industry
Biotechnology
IPO Date
Nov 17, 2017
CEO
John Tucker
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
SCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is 11.00, which is an increase of 55.59% from the latest price.

Price Target
$11.00
(55.59% upside)
Analyst Consensus: Buy